Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401182 | 0.99 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL6889085 | 0.99 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL887559 | 0.99 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29458423 | 0.99 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL230688 | 0.96 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31031901 | 0.96 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29468684 | 0.96 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL793384 | 0.93 | KMT2A (0.85) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL163534 | 0.90 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL17971325 | 0.89 | KMT2A (0.74) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681777-A2 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2026-01-21 | — | — | EP | disclosed |
| EP-3737665-B1 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2026-01-07 | — | — | EP | disclosed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20240400684-A1 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| US-20240398962-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY (CZ) | 2024-12-05 | — | — | US | disclosed |
| WO-2024040169-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4322961-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G | 2007-05-17 | — | — | US | disclosed |
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G | 2007-05-17 | — | — | US | disclosed |
| US-7122549-B2 | Saframycins, analogues and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2006097320-A2 | MACROMOLECULAR NUCLEOTIDE LINKS AND METHODS FOR THEIR USE | GENOVOXX GMBH (DE) | 2006-09-21 | — | — | WO | disclosed |
| US-6809099-B2 | FOR THERAPY OF CANCER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-10-26 | — | — | US | disclosed |
| US-20040204419-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G (US) | 2004-10-14 | — | — | US | disclosed |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | ARIAD PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| EP-1339713-A2 | SAFRAMYCINS, ANALOGUES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030008873-A1 | Saframycins, analogues and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002040477-A2 | SAFRAMYCINS, ANALOGUES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204419-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | KMT2A 3777/4885EPHX2 3737/4885FABP7 2566/4885 |
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | KMT2A 3796/4885EPHX2 3637/4885FABP7 2542/4885 |
| US-20030008873-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | KMT2A 3777/4885EPHX2 3737/4885FABP7 2566/4885 |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | SRC, CTTN, YES1 | KMT2A 1865/4885EPHX2 4197/4885FABP7 4354/4885 |
| US-20240398962-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | GLUL, GLS, GRM2 | KMT2A 398/4885EPHX2 4017/4885FABP7 363/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | KMT2A 2167/4885EPHX2 2080/4885FABP7 1242/4885 |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | KMT2A 3085/4885EPHX2 1836/4885FABP7 877/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | KMT2A 3085/4885EPHX2 1836/4885FABP7 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.